IPSC

#3144
Century Therapeutics, Inc. - Common Stock
2.0 3 USD
-0.09%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.03
2.03
Intervallo Annuale
0.44
3.03
Variazione giornaliera
-8.97%
Variazione Mensile
-0.49%
Variazione di 6 mesi
-9.38%
Variazione Annuale
+314.29%
Chiusura Precedente
2.2 3
Open
2.0 3
Minimo
2.0 3
Massimo
2.0 3
Volume
34
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Century Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Century Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Century Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K

Century Therapeutics, Inc. current report, Q2 FY2024

Full document

Century Therapeutics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated June 20, 2024, details the results of Century Therapeutics, Inc.'s 2024 Annual Meeting of Stockholders. The meeting was conducted virtually. As of the record date of April 24, 2024, there were 82,847,375 outstanding shares of common stock.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

The following proposals were submitted to and approved by stockholders:

  • Proposal 1: Election of Class III Directors
    • Kimberly Blackwell, M.D.: Elected with 59,931,468 votes For, 0 Against, and 6,014,484 Abstentions.
    • Joseph Jimenez: Elected with 64,376,622 votes For, 0 Against, and 1,569,330 Abstentions.
    • Brent Pfeiffenberger, Pharm.D.: Elected with 65,728,988 votes For, 0 Against, and 216,964 Abstentions.
    • All three directors will serve until the 2027 Annual Meeting.
  • Proposal 2: Ratification of Independent Registered Public Accountant
    • Ernst & Young LLP was ratified for the 2024 fiscal year with 72,250,603 votes For, 1,065,984 Against, and 24,413 Abstentions.
  • Proposal 3: Approval of Certificate of Amendment
    • Stockholders approved an amendment to the Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers under Delaware law.
    • Voting results: 64,419,117 For, 1,488,443 Against, and 38,391 Abstentions.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, or specific risk factors beyond the standard governance disclosures.

Key Facts for Investor Verification

  • Verify the terms of the Certificate of Amendment regarding officer liability limitations.
  • Confirm the tenure and specific responsibilities of the newly elected Class III directors.
  • Review the Definitive Proxy Statement on Schedule 14A (filed April 26, 2024) for detailed background on the proposals.
  • Note the significant number of broker non-votes (approx. 7.4 million) on director elections and the Certificate of Amendment.

Notizie